• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20001 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2000     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Influenza vaccination of the elderly (funded by DIHTA)]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Influence of an existing health care plan aimed at managing ST-elevation myocardial infarction on the waiting time until re-perfusion, and types of re-perfusion. Pilot study]
2007     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Infliximab in patients with arthritis psoriatic: systematic review of the clinical and economic literature]
2004     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Infliximab (REMICADE) in patients with rheumatoid arthritis; systematic review of the clinical and economic literature]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Induction of labour versus expectant management in women with preterm premature rupture of membranes between 34 and 37 weeks (PPROMEXIL-study)]
2012     The Regional Health Technology Assessment Centre (HTA-centrum) [Induction of labour at 41 completed until 42 completed gestational weeks, update of mini-HTA VGR 2007]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Induced sputum in severe asthma patients]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Individualised multidisciplinary care programme in frail patients (PAMI)]
2011     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Individual health services]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Indirect comparisons of therapeutic interventions]
2013     National Evidence-based Healthcare Collaborating Agency (NECA) [Indirect comparison methodology research for health technology assessment: Comparison of drug treatment effect in adult attention deficit hyperactivity disorder using a common comparator]
2019     Basque Office for Health Technology Assessment (OSTEBA) [Indications, utility and use of ultrasound in primary care]
2011     Institut national d'excellence en sante et en services sociaux (INESSS) [Indications for positron emission tomography (pet): a brief update]
2008     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Indications for hyperbaric oxygen therapy: update]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Indications and recommendations for the use of PET-CT in the planning of radiation oncology treatment. Systematic review]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Addendum to Commission A20-69]
2011     Andalusian Health Technology Assessment Area (AETSA) [Inclusion of new health technologies into Spanish hospitals]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inclisiran (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Incidence of errors in intensive care: effects of increased awareness and of improved communication by the introduction of explicit daily goals]
2006     Basque Office for Health Technology Assessment (OSTEBA) [Incidence of diabetic retinopathy based on a screening programme using a non-mydriatic retinal camera on diabetic patients in the Autonomous Community of the Basque Country]
2009     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [In vitro fertilization: comparative profile of European and Oceania countries]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Improving the efficiency and quality of follow-up after curative treatment for breast cancer]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Improving the early diagnosis of myocardial infarction in primary care: the added value of a rapid assay to detect heart-type FABP, a novel marker of cardiac injury]
2009     Basque Office for Health Technology Assessment (OSTEBA) [Improving the care of elderly patients with chronic pathologies]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Improving lifestyle adherence in patients with high risk for cardiovascular diseases in general practice. Costs and effects of patient involvement in cardiovascular risk management]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementing a routine outcome monitoring system to study the effectiveness of long-term psychoanalytic treatment and therapeutic decision making in four cohorts of personality disordered and/ or recurrent or chronic depressive patients]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of the WIP guideline 'Prevention of infections due to urethral bladder catheterization']
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of structural feedback by means of perinatal audit to caregivers in cases of perinatal mortality in the northern part of the Netherlands (IMPACT)]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of selective karyotyping in couples with recurrent miscarriage]
2012     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of screening and treatment of high-risk fracture patients by an osteoporosis nurse-practitioner]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Implementation of quality indicators to assess the high risk of colorectal cancer clinic]
2012     The Swedish Council on Health Technology Assessment (SBU) [Implementation of psychiatric guidelines and evidence-based knowledge in the primary care sector]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of outpatient schema focused therapy for borderline personality disorder in three settings: general community mental health centers, forensic centers and addiction treatment centers]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of intensive insulin therapy (IIT) in critically ill patients, targeting at normoglycemia while preventing hypoglycemia]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implementation of guidelines - obstructive and beneficial factors]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of evidence-based guidelines for appropriate use of ultrasonography in diagnostic breast imaging: the MAMMOED-2 study]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of an evidence based smoking cessation strategy (SMOCC) for patients with COPD in primary care]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [IMPlementation of a prediction rule in Anesthesia practice to improve Cost-effectiveness of Treatment of postoperative nausea and vomiting: the IMPACT trial]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of a new cost-effective treatment (HIT) for patients with therapy refractory auditory hallucinations]
2012     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of a multiple intervention aimed at optimising prescription of antibiotics for respiratory tract infections, embedded within the new practice accreditation of the Dutch College of General Practitioners; a randomized controlled trial]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Implementation and development of a treatment programme for peritoneal carcinomatosis in Catalonia. Indications and clinical results using Sugarbaker's technique]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implantation via injection under endoscopic ultrasound guidance of 32P-labeled microparticles for unresectable, locally advanced pancreatic tumours]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implantation via injection under endoscopic ultrasound guidance of 32P-labeled microparticles for unresectable, locally advanced pancreatic tumours - Addendum to commission H21-13]
2009     Committee for New Health Technology Assessment (CNHTA) [Implantation technology of autologous chondrocyte using fibrin]
2014     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Implantation of a permanent embolic protection in patients with non-valvular attrial fibrillation in left auricular appendage]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Implantation of a lumbar artificial endoprosthesis (anuloplasty/anular repair device)]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Implantable ventricular assist devices: assessment of evidence and required elements to establish a clinical registry in Québec]
2008     Committee for New Health Technology Assessment (CNHTA) [Implantable drug infusion pump implantation]
1999     Andalusian Health Technology Assessment Area (AETSA) [Implantable defibrillators: criteria for clinical indications and decision making on coverage - non-systematic review]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Implantable cardiac monitors in syncope of unknown etiology]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Implantable cardiac defibrillator for primary prevention of sudden death]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Implantable and programmable sacral neuromodulator (Interstim®) treatment of urinary, fecal and combined incontinence]
2011     Andalusian Health Technology Assessment Area (AETSA) [Impella Recover® 2.5 ventricular assist device]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Impact of the implementation of EFQM in Osakidetza]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Impact of the implementation of a population-based cervical cancer screening program based on European recommendations (test/interval) with regard to the current situation]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Impact of HTA-research in Austria for the health care system. Part 1: Overview - Update]
2012     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Impact of day care centres in monitoring patients with Obstructive Sleep Apnea Syndrome (OSAS)]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Impact of clinical and health services research in advancing knowledge. Applied study to the CAHTA research calls]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Impact of clinical and health services research in advancing knowledge. Applied study to the CAHTA research calls (second edition)]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Impact of clinical and health services research calls on informing decision-making and capacity building. The viewpoint of the researchers]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Impact of a prioritization system for patients on waiting list for hip and knee arthroplasties and cataract surgery]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Impact from HTA-research for the Austrian health care system. Part 2: Results of the empirical survey]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Impact evaluation of optimal use guidelines implementation for self-monitoring of blood glucose by adult patients with type 2 diabetes and not using insulin]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Immunological faecal occult blood test for patients with symptoms compatible with colorectal cancer: recommendation of Clinical Practice Guides and use in the National Health System]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Immunoglobulin in patients with post-polio syndrome]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Immunoglobulin in chronic inflammatory demyelinating polyneuropathy and other neurological conditions]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Immunoglobulin for myasthenia gravis chronic treatment]
2010     Andalusian Health Technology Assessment Area (AETSA) [Immunogenicity and safety of prepandemic vaccines against H5N1 avian flu]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Immunocyanin in urothelial bladder cancer
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Immunochemical fecal occult blood. Determination of a positivity threshold for the upcoming demonstration projects under Québec's colorectal cancer screening program]
2010     Andalusian Health Technology Assessment Area (AETSA) [Immunisation against angiotensin II. A therapeutic vaccine against arterial hypertension]
2005     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Immediate breast reconstruction. Systematic review and evaluation of results in a RMI unit in the Community of Madrid]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Imlifidase (kidney transplantation) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Imipenem/cilastatin/relebactam (bacterial infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Imatinib in the treatment of chronic myelogenous leukemia]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Imatinib for gastro-intestinal stromal tumors]
2013     The Regional Health Technology Assessment Centre (HTA-centrum) [Image-guided system for endoscopic sinus surgery]
2022     Basque Office for Health Technology Assessment (OSTEBA) [Image-guided spinal fusion technology]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Image-guided radiosurgery and radiotherapy for central nervous systems tumors]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Image-guided radiation therapy in liver and lung tumors]
2009     Committee for New Health Technology Assessment (CNHTA) [IL2RG gene mutation analysis]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Idursulfase (Elaprase) in the treatment of mucopolisacaridosis II
2008     Committee for New Health Technology Assessment (CNHTA) [IDUA gene, mutation[sequencing]]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [Identifying optimal diagnostic strategies algorithms with multiple tests. Ancillary study of Optimisation of diagnostic imaging use in patients with acute abdominal pain: cost-effectiveness analysis of imaging strategies (OPTIMA study)]
2012     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Identifying opportunities for health care disinvestment]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Identifying ineffective interventions and health technologies: models and their implementation]
2019     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Identification of psychosocial practices and interventions that support the adaptation and rehabilitation of adults with Prader-Willi Syndrome]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Identification of preventive health care for children and young people]
2021     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Identification of factors influencing the risk of absconding in a user with an intellectual disability, autism spectrum disorder or a mental health disorder]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idelalisib: benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idelalisib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idelalisib (chronic lymphocytic leukaemia) - Addendum to Commission A16-18]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idecabtagene vicleucel (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idebenone: assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2012     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Idebenone for the treatment of Friedreich's ataxia]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idebenone (Leber hereditary optic neuropathy) - assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Icosapent ethyl (hypertriglyceridaemia) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Icosapent ethyl (cardiovascular risk reduction) - Addendum to Commission A21-113]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]